CJC-1295 + GHRP-2 (10 mg Blend) Dosage Protocol
CJC-1295 + GHRP-2 (10 mg Blend) Dosage Protocol
CJC-1295 + GHRP-2 Dosage Chart
The CJC-1295 + GHRP-2 peptide blend is dosed at 150 mcg–300 mcg daily via subcutaneous injection in educational protocols. A 10 mg blend reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.
Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration (1 unit ≈ 33.3 mcg).
Typical daily range: 100–300 mcg once daily (gradual titration).
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F) for long-term; after reconstitution, refrigerate and use within 2–4 weeks.
CJC-1295 is a long-acting GHRH analog that can elevate GH levels 2–10× baseline for approximately 6 days and increase IGF-1 by 1.5–3× for 9–11 days[1]. GHRP-2 is a ghrelin-mimetic secretagogue with a plasma half-life of ~30 minutes that triggers rapid GH pulses peaking within ~25 minutes of administration[3]. Combining these peptides leverages GHRP-2’s acute pulsatile release with CJC-1295’s sustained action. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.
Related research: For distinct compound, component, or formulation evidence and safety context, read What Is GHRP-2? Mechanism, Benefits, Risks, and Alternatives and CJC-1295 DAC Peptide: Benefits, Uses, Side Effects, Dosage, and Research. These links are comparisons only; the compounds and formulations should not be treated as interchangeable.
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
Weeks 1–2
150 mcg (0.15 mg)
4.5 units (0.045 mL)
Weeks 3–12
300 mcg (0.30 mg)
9 units (0.09 mL)
Frequency: Tie timing to the research design. Human work supports acute synergistic GH release when GHRH and a growth hormone-releasing peptide are combined[6]. The cited study used controlled intravenous administration and does not define a bedtime subcutaneous schedule for this exact blend.
Reconstitution Steps
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Advanced / Twice-Daily Approach (3 mL = ~3.33 mg/mL)
Some protocols split the daily dose into two administrations (morning upon waking, fasted; and evening before bed) to enhance GH pulsatility[1]. Ensure doses are at least 3–8 hours apart to avoid overlapping GH pulses.
100 mcg (0.10 mg)
3 units (0.03 mL)
200 mcg
300 mcg
For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration (once-daily schedule).
Peptide Vials (CJC-1295 + GHRP-2, 10 mg each):
8 weeks ≈ 2 vials
12 weeks ≈ 3 vials
16 weeks ≈ 4 vials
Insulin Syringes (U-100):
Per week: 7 syringes (1/day)
8 weeks: 56 syringes
12 weeks: 84 syringes
16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
12 weeks (3 vials): 9 mL → 1 × 10 mL bottle
16 weeks (4 vials): 12 mL → 2 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
Per week: 14 swabs (2/day)
8 weeks: 112 swabs → recommend 2 × 100-count boxes
12 weeks: 168 swabs → recommend 2 × 100-count boxes
16 weeks: 224 swabs → recommend 3 × 100-count boxes